Hook and thesis
Elbit Systems (ESLT) is no longer a cyclical defense name waiting for a procurement cycle - the recent Iran strikes have turned demand into a structural tailwind. The market reacted immediately: defense suppliers rallied in early March and Elbit, the Israeli prime supplier for drones, ISR and active protection systems, sits at the center of that re-rating. We think this is more than a short-lived pop. Backlog, contract wins and an accelerating procurement cycle in the U.S. and Israel create a multi-quarter revenue runway that justifies a tactical upgrade.
That said, shares are richly priced and technically extended. This is a trade, not a blind buy-and-hold. We upgrade to a buy with a clearly defined entry at $920.00, a protective stop at $860.00 and a target of $1,040.00 over a long-term trade horizon. Risk management and position sizing are essential.
What the company does - and why the market should care
Elbit Systems Ltd develops airborne, land and naval systems and supplies them to defense and homeland-security customers. Its product set spans unmanned aerial systems (drones), electro-optics, avionics, command-and-control, and active protection systems for armored vehicles. Elbit also provides training and sustainment services.
Why the market should care: defense procurement is event-driven and predictable once governments decide to spend. Regional conflict - in this case the Iran strikes - shortens procurement lead times and expands budgets for ISR, counter-drone and missile-defense systems. Elbit is a direct beneficiary given its role as a primary drone supplier to the Israeli Defense Forces and a contractor with significant exposure to U.S. programs.
Supporting numbers
- Market capitalization stands at roughly $42.66 billion.
- Shares outstanding: 46,462,900; float: ~26.88 million shares.
- Current share price: $920.19 (previous close $936.14). 52-week range: $343.00 - $960.00.
- Valuation metrics show a high multiple environment: P/E ~95.1 and P/B ~10.8, reflecting growth expectations and backlog conversion.
- Backlog: $25.2 billion as of 09/30/2025 - a significant revenue visibility buffer for the next several years.
- Recent contract wins: approximately $435 million in new contracts announced on 02/17/2026 and a $228 million award tied to Iron Fist active protection systems (announced 01/26/2026), totaling roughly $663 million in near-term awards cited by the company and press.
- Technicals: 10-day SMA $833.32, 20-day SMA $765.28, 50-day SMA $710.82; the 9-day EMA $854.45 and 21-day EMA $791.17 are both rising, indicating momentum. MACD is bullish with a MACD line of 59.18 above the signal at 41.02 and a histogram of 18.15. RSI sits at 80.21, signaling an overbought condition and the need for disciplined entry sizing.
- Volume profile: today's volume ~219,763 vs a 2-week average of ~255,876 and a 30-day average of ~198,396; short interest has generally declined from prior peaks, latest settlement showing ~142,422 shares short (days to cover ~1.19), consistent with limited structural short pressure.
Valuation framing
At a $42.66 billion market cap and a P/E near 95, the market is pricing meaningful growth and/or sustained margin expansion into the next several years. On face, that multiple is high versus traditional defense contractors, but two facts mitigate the premium:
- Order backlog of $25.2 billion provides revenue visibility and de-risks near-term top-line delivery.
- Recent contract wins totaling roughly $663 million add to the backlog and signal active procurement by both Israeli and U.S. customers.
Absent direct peer multiples in this note, think of valuation qualitatively: Elbit is trading like a high-growth defense prime rather than a low-single-digit growth contractor. That premium can be warranted if backlog converts into above-market revenue growth and margins hold, but it also elevates downside should the geopolitical premium fade.
Catalysts
- Contract accrual and confirmations - follow-on announcements after the $435 million award (02/17/2026) and the earlier $228 million deal could materially increase booked revenue.
- U.S. procurement actions - increased U.S. funding for drone and active protection programs would materially expand Elbit's addressable market.
- Backlog conversion - quarterly bookings and conversion into revenue will be the primary fundamental driver of earnings upside over the next 1-4 quarters.
- Technology wins - export approvals or integration contracts tied to missile-defense and counter-UAS systems can accelerate growth and validate the valuation premium.
Trade plan (actionable)
We view this as a long-biased tactical trade with the following execution parameters:
| Action | Level |
|---|---|
| Entry | $920.00 |
| Stop Loss | $860.00 |
| Target | $1,040.00 |
| Horizon | Long term (120 trading days) |
| Risk Level | Medium |
Why this horizon: the backlog and contract pipeline suggest revenue and earnings accretion that unfolds over multiple quarters. A 120 trading day horizon (~6 months) allows time for announced contracts to be booked, early delivery milestones to be reported, and for institutional investors to re-rate the name if growth is confirmed. Because RSI sits above 80 and price is near the 52-week high ($960.00), the stop at $860.00 limits downside to roughly -6.5% from entry while leaving room for normal intraday volatility.
Counterargument
There is a plausible bear case: the market could be pricing a short-term geopolitical premium rather than long-lived structural demand. If tensions de-escalate or if governments prioritize domestic suppliers or diversify away from Israeli systems for political reasons, the premium could compress quickly. Moreover, the P/E of ~95 implies the company must deliver sustained growth and margin expansion - any revenue misses or execution hiccups would likely cause steep multiple contraction.
Risks
- Geopolitical de-escalation - if the Iran conflict cools and defense budgets are not expanded, the surge in demand may be transitory and shares could revert sharply.
- Valuation risk - the market is paying a premium (P/E ~95; P/B ~10.8). Execution misses on backlog conversion or margin pressure could lead to disproportionate downside.
- Program execution risk - complex defense contracts can face delays, cost overruns or technical setbacks that push revenue out and depress margins.
- Export and political risk - defense sales depend on export approvals and government-to-government agreements; any change in export policy or diplomatic friction could limit addressable markets.
- Technical/market risk - RSI at 80.21 signals overbought conditions and heightens the chance of a short-term pullback. Volatility may spike around newsflow.
What would change our view
We will downgrade the trade if any of the following occur: a) material evidence that booked contracts are being delayed or cancelled, b) sequential backlog erosion instead of growth, c) a visible macro de-risking where major customers pull back procurement budgets, or d) a sustained technical breakdown below $860 with volume confirming distribution. Conversely, additional multi-hundred-million-dollar awards, visible order-book conversion in quarterly results, or meaningful U.S. program wins would reinforce our bullish stance and justify adding to the position.
Conclusion
Elbit Systems sits at the intersection of an active geopolitical shock and multi-year defense modernization trends. The company's $25.2 billion backlog, recent contract awards totaling roughly $663 million, and clear role in drones, active protection and ISR argue for a tactical upgrade. That said, the stock is richly valued and technically extended, so this is a disciplined trade: entry $920.00, stop $860.00, target $1,040.00, long-term (120 trading days) horizon. Position size appropriately and treat the trade as a directional but event-driven opportunity rather than a low-volatility, long-duration hold.
Trade with conviction, but manage the downside. The Iran war changed the trajectory for some defense names - Elbit is one of them - but the market will demand conversion of backlog into results to sustain the premium.